11.99
Viridian Therapeutics Inc (VRDN) 最新ニュース
Stifel maintains Buy on Viridian Therapeutics, $41 target By Investing.com - Investing.com Canada
(VRDN) Trading Report - news.stocktradersdaily.com
Teacher Retirement System of Texas Boosts Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Financial Analysis: Viridian Therapeutics (NASDAQ:VRDN) versus ACI Global (OTCMKTS:ACGJ) - Defense World
Quantbot Technologies LP Invests $164,000 in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Acquired by Swiss National Bank - Defense World
Raymond James Financial Inc. Makes New $6.02 Million Investment in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Where are the Opportunities in (VRDN) - news.stocktradersdaily.com
Charles Schwab Investment Management Inc. Raises Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
AlphaQuest LLC Acquires 1,519 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Commit To Buy Viridian Therapeutics At $12.50, Earn 13.2% Annualized Using Options - Nasdaq
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by Bank of New York Mellon Corp - Defense World
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Bought by Arizona State Retirement System - Defense World
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
410,440 Shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN) Acquired by Victory Capital Management Inc. - Defense World
Viridian Therapeutics at Leerink’s Conference: Progress in TED Treatments By Investing.com - Investing.com UK
Viridian Therapeutics appoints new director, sees board resignation By Investing.com - Investing.com South Africa
Viridian Therapeutics Announces Inducement Stock Option Grants - Nasdaq
Viridian Therapeutics appoints new director, sees board resignation - Investing.com India
What is B. Riley’s Forecast for VRDN Q1 Earnings? - Defense World
Principal Financial Group Inc. Has $3.42 Million Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
What is B. Riley’s Estimate for VRDN Q2 Earnings? - Defense World
Decoding Viridian Therapeutics Inc (VRDN): A Strategic SWOT Insi - GuruFocus.com
Viridian Therapeutics inks new $300M sales agreement By Investing.com - Investing.com South Africa
Viridian Therapeutics Terminates Prior $175 Million Sale Agreement -March 04, 2025 at 06:36 am EST - Marketscreener.com
Viridian Therapeutics Enters New $300M Sale Agreement - TipRanks
Viridian Therapeutics inks new $300M sales agreement - Investing.com
Rhumbline Advisers Has $1.92 Million Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Viridian Therapeutics Faces Uncertainty Amid Regulatory Approval Challenges - TipRanks
Viridian Therapeutics, Inc.\DE SEC 10-K Report - TradingView
Q1 EPS Estimates for Viridian Therapeutics Raised by Wedbush - Defense World
How to Take Advantage of moves in (VRDN) - Stock Traders Daily
Viridian Therapeutics: Positive Data In TED, Strong Cash Position, 1.5-Year Window - Seeking Alpha
FY2027 EPS Forecast for Viridian Therapeutics Cut by Analyst - Defense World
Viridian Therapeutics (NASDAQ:VRDN) Posts Earnings Results, Beats Expectations By $0.24 EPS - MarketBeat
RBC Capital Adjusts Viridian Therapeutics Price Target to $46 From $47, Maintains OutperformSpeculative Risk Rating - Marketscreener.com
Viridian Therapeutics: Promising Market Position and Growth Prospects Justify Buy Rating - TipRanks
Viridian Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance UK
Viridian Therapeutics Reports Strong Progress and Financials - TipRanks
Viridian Therapeutics: Strong Financials and Promising Clinical Developments Drive Buy Rating - TipRanks
Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Lags Revenue Estimates - MSN
Viridian Therapeutics reports Q4 EPS (81c), consensus ($1.04) - TipRanks
Viridian Therapeutics Positioned for Market Leadership with Strategic Advancements and Competitive Edge - TipRanks
Viridian Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
VRDNViridian Therapeutics Inc Latest Stock News & Market Updates - StockTitan
Viridian Therapeutics: Strong TED Trial Results and Promising Pipeline Drive Buy Rating - TipRanks
Viridian Therapeutics' Q4 Net Loss Narrows, Revenue Flat -February 27, 2025 at 09:27 am EST - Marketscreener.com
Earnings Flash (VRDN) Viridian Therapeutics Posts Q4 Revenue $72,000 -February 27, 2025 at 07:20 am EST - Marketscreener.com
Earnings Flash (VRDN) Viridian Therapeutics Posts Q4 Net Loss $0.81 a Share, vs. FactSet Est of $1.05 Loss - Marketscreener.com
Viridian Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results - Business Wire
Viridian Therapeutics Becomes Oversold (VRDN) - Nasdaq
Viridian Therapeutics (VRDN) Projected to Post Quarterly Earnings on Tuesday - Defense World
Analysts Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) Price Target at $35.70 - MarketBeat
大文字化:
|
ボリューム (24 時間):